Pimco President Christian Stracke discusses the firm's expansion of its international business. Speaking at the Milken Institute Global Conference in Beverly Hills, California, Stracke says international clients are seeking to diversify away from US markets amid geopolitical shifts. (Source: Bloomberg)
Pimco President Christian Stracke discusses the firm's expansion of its international business. Speaking at the Milken Institute Global Conference in Beverly Hills, California, Stracke says international clients are seeking to diversify away from US markets amid geopolitical shifts. (Source: Bloomberg)
ozgurcankaya/iStock via Getty Images Johnson & Johnson ( JNJ ) said that a network meta-analysis found that its antipsychotic Caplyta ( lumateperone) performed the best in terms of efficacy compared to other treatments used as add-on therapies to treat major depressive disorder. That assessment was based on four measures from indirect comparisons from placebo plus antidepressant therapy-controlled...
ozgurcankaya/iStock via Getty Images Johnson & Johnson ( JNJ ) said that a network meta-analysis found that its antipsychotic Caplyta ( lumateperone) performed the best in terms of efficacy compared to other treatments used as add-on therapies to treat major depressive disorder. That assessment was based on four measures from indirect comparisons from placebo plus antidepressant therapy-controlled trials. An NMA provides an evaluation based on separate placebo-controlled trials. Caplyta was compared to drugs including Abilify (aripiprazole), Rexulti (brexpiprazole), Vraylar (cariprazine), and Seroquel (quetiapine). J&J said that as an add-on treatment, Caplyta had the best efficacy of the bunch in terms of Montgomery-Åsberg Depression Rating Scale (MADRS) score, MADRS response, MADRS remission, and change from baseline in Clinical Global Impression-Severity (CGI-S) score More on Johnson & Johnson Johnson & Johnson: Why I See Downside Ahead Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript Johnson & Johnson Q1 Earnings Review: Why You Should Be Buying The Stock Today Most and least shorted mid-to mega-cap healthcare stocks in May J&J ends development for several CAR-T large B-cell lymphoma programs
The Baldwin Insurance Group press release ( BWIN ): Q1 Non-GAAP EPS of $0.63 in-line. Revenue of $532.2M (+28.7% Y/Y) beats by $8.44M . More on The Baldwin Insurance Group Baldwin Insurance: AI Fears Are Exaggerated (Upgrade) The Baldwin Insurance Group, Inc. (BWIN) Q4 2025 Earnings Call Transcript The Baldwin Insurance Group, Inc. 2025 Q4 - Results - Earnings Call Presentation Baldwin stock jumps...
The Baldwin Insurance Group press release ( BWIN ): Q1 Non-GAAP EPS of $0.63 in-line. Revenue of $532.2M (+28.7% Y/Y) beats by $8.44M . More on The Baldwin Insurance Group Baldwin Insurance: AI Fears Are Exaggerated (Upgrade) The Baldwin Insurance Group, Inc. (BWIN) Q4 2025 Earnings Call Transcript The Baldwin Insurance Group, Inc. 2025 Q4 - Results - Earnings Call Presentation Baldwin stock jumps on expanded Anthropic relationship for Claude deployment Baldwin Group outlines $2B revenue target for 2026, accelerates AI integration after AI-driven market disruption
James River press release ( JRVR ): Q1 Non-GAAP EPS of $0.12 misses by $0.15 . Revenue of $151.38M (-12.1% Y/Y) misses by $14.84M . Shares -11% AH. More on James River James River Group Holdings, Inc. (JRVR) Q4 2025 Earnings Call Transcript James River outlines mid-teen return on equity target through technology and expense discipline Seeking Alpha’s Quant Rating on James River Historical earnings...
James River press release ( JRVR ): Q1 Non-GAAP EPS of $0.12 misses by $0.15 . Revenue of $151.38M (-12.1% Y/Y) misses by $14.84M . Shares -11% AH. More on James River James River Group Holdings, Inc. (JRVR) Q4 2025 Earnings Call Transcript James River outlines mid-teen return on equity target through technology and expense discipline Seeking Alpha’s Quant Rating on James River Historical earnings data for James River Dividend scorecard for James River
June WTI crude oil (CLM26 ) on Monday closed up +4.48 (+4.39%), and June RBOB gasoline (RBM26 ) closed up +0.1430 (+3.98%). Crude oil and gasoline prices recovered from overnight losses and moved sharply higher on signs of heightened tensions in the Strait of Hormuz. Crude prices shot higher Monday...
June WTI crude oil (CLM26 ) on Monday closed up +4.48 (+4.39%), and June RBOB gasoline (RBM26 ) closed up +0.1430 (+3.98%). Crude oil and gasoline prices recovered from overnight losses and moved sharply higher on signs of heightened tensions in the Strait of Hormuz. Crude prices shot higher Monday...
Michael Mente, Co-Chief Executive Officer of Revolve Group (NYSE:RVLV) , reported the indirect sale of 119,241 Class A shares through open-market transactions totaling approximately $3.14 million, as disclosed in a SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($26.34); post-transaction value based on April 29, 2026, market close ($1,882,670.00). * 1-yea...
Michael Mente, Co-Chief Executive Officer of Revolve Group (NYSE:RVLV) , reported the indirect sale of 119,241 Class A shares through open-market transactions totaling approximately $3.14 million, as disclosed in a SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($26.34); post-transaction value based on April 29, 2026, market close ($1,882,670.00). * 1-year price change calculated using April 29, 2026, as the reference date. Continue reading
Repay press release ( RPAY ): Q1 GAAP EPS of -$0.12 misses by $0.09 . Revenue of $80.8M (+4.5% Y/Y) beats by $0.32M . Initial Full Year 2026 Outlook from March 9th Updated Full Year 2026 Outlook Revenue $340 - 346 million $340 - 346 million Adjusted EBITDA $136.5 - 141.5 million $141 - 146 million Free Cash Flow Conversion 45% 45% Click to enlarge More on Repay Repay Holdings: Attractive Valuation...
Repay press release ( RPAY ): Q1 GAAP EPS of -$0.12 misses by $0.09 . Revenue of $80.8M (+4.5% Y/Y) beats by $0.32M . Initial Full Year 2026 Outlook from March 9th Updated Full Year 2026 Outlook Revenue $340 - 346 million $340 - 346 million Adjusted EBITDA $136.5 - 141.5 million $141 - 146 million Free Cash Flow Conversion 45% 45% Click to enlarge More on Repay Repay Holdings: Attractive Valuation Amid M&A Activity Repay Holdings Corporation (RPAY) M&A Call Transcript Repay Holdings Corporation (RPAY) Repay Holdings Corporation - M&A Call - Slideshow Repay rejects unsolicited proposal from Forager Capital Repay stock jumps 11% after preliminary Q1 adjusted EBITDA tops consensus
Earnings Call Insights: RLJ Lodging Trust (RLJ) Q1 2026 Management View "We are encouraged to see the lodging industry off to a strong start this year, benefiting from the underlying strength of fundamentals, with the acceleration of business transient demand being a key driver." (President, CEO & Trustee Leslie D. Hale) "During the first quarter, we achieved RevPAR growth of 4.8%, outperforming t...
Earnings Call Insights: RLJ Lodging Trust (RLJ) Q1 2026 Management View "We are encouraged to see the lodging industry off to a strong start this year, benefiting from the underlying strength of fundamentals, with the acceleration of business transient demand being a key driver." (President, CEO & Trustee Leslie D. Hale) "During the first quarter, we achieved RevPAR growth of 4.8%, outperforming the industry by 100 basis points." (President, CEO & Trustee Hale) "Northern California achieved outstanding RevPAR growth of 27%, benefiting not only from the Super Bowl ... but also from the continued expansion of the AI industry, which is driving significant corporate investment and business travel demand." (President, CEO & Trustee Hale) "Our portfolio also generated outsized non-room revenue growth of 8.2%." (President, CEO & Trustee Hale) "During the quarter, we saw meaningful strength within our urban markets, which achieved 4.4% RevPAR growth" and "our non-room revenues generate strong margins, which improved by 130 basis points during the quarter." (Senior VP, CFO & Treasurer Nikhil Bhalla) "We remain on track to relaunch the property under Marriott's Autograph Collection this summer" (Renaissance Pittsburgh) and "we are on pace to begin construction later this year" (Wyndham Boston to Hilton Tapestry). (President, CEO & Trustee Hale) Outlook "For 2026, we now expect comparable RevPAR growth to range between 1.5% and 3.5%, comparable hotel EBITDA between $356 million and $380 million, corporate adjusted EBITDA between $324 million and $348 million and adjusted FFO per diluted share to be between $1.29 and $1.45." (Senior VP, CFO & Treasurer Bhalla) "We have incorporated our strong first quarter out-performance into our revised guidance while keeping our expectations for the remainder of the year unchanged from our prior outlook." (Senior VP, CFO & Treasurer Bhalla) "In light of our strong first quarter results, our adjusted EBITDA contribution for the second quarter...
Corebridge Financial press release ( CRBG ): Q1 Non-GAAP EPS of $1.05 misses by $0.01 . Revenue of $4.08B (-7.3% Y/Y). More on Corebridge Financial Corebridge Financial, Inc. (CRBG) Equitable Holdings, Inc. - M&A Call - Slideshow Corebridge Financial, Inc. (CRBG) M&A Call Transcript Corebridge: Aggressive Buybacks Set To Continue Corebridge Financial appoints Christopher Filiaggi as interim CFO Co...
Corebridge Financial press release ( CRBG ): Q1 Non-GAAP EPS of $1.05 misses by $0.01 . Revenue of $4.08B (-7.3% Y/Y). More on Corebridge Financial Corebridge Financial, Inc. (CRBG) Equitable Holdings, Inc. - M&A Call - Slideshow Corebridge Financial, Inc. (CRBG) M&A Call Transcript Corebridge: Aggressive Buybacks Set To Continue Corebridge Financial appoints Christopher Filiaggi as interim CFO Corebridge and Equitable strike all-stock merger deal valuing combined firm at $22B
Former CFTC Commissioner and current Kalshi board member Brian Quintenz discusses the evolving landscape of prediction markets and how federally regulated prediction markets and state-regulated sports books can coexist. He talks with Katie Greifeld and Romaine Bostick at the Milken Institute Global Conference in Beverly Hills, California. (Source: Bloomberg)
Former CFTC Commissioner and current Kalshi board member Brian Quintenz discusses the evolving landscape of prediction markets and how federally regulated prediction markets and state-regulated sports books can coexist. He talks with Katie Greifeld and Romaine Bostick at the Milken Institute Global Conference in Beverly Hills, California. (Source: Bloomberg)
TOP Financial Group Limited ( Nasdaq: TOP ) on Monday said it has received a notice from Nasdaq Stock Market LLC for failing to meet the minimum bid price requirement. The company said its shares traded below $1.00 for 30 consecutive business days, triggering non-compliance with listing rules. TOP Financial added it has 180 days, until October 26, 2026, to regain compliance, and said the notice do...
TOP Financial Group Limited ( Nasdaq: TOP ) on Monday said it has received a notice from Nasdaq Stock Market LLC for failing to meet the minimum bid price requirement. The company said its shares traded below $1.00 for 30 consecutive business days, triggering non-compliance with listing rules. TOP Financial added it has 180 days, until October 26, 2026, to regain compliance, and said the notice does not affect current trading or operations. Source: Press Release More on TOP Financial Group Financial information for TOP Financial Group
Edwards Lifesciences ( EW ) appointed Theodora Mistras as chief financial officer effective end of May 2026. Mistras joins from Viatris ( VTRS ), where she served as CFO since 2024. She succeeds Scott Ullem, who is transitioning after over a decade in the role. Mistras brings extensive experience in healthcare finance, including roles at Citigroup Global Markets and Goldman Sachs. More on Edwards ...
Edwards Lifesciences ( EW ) appointed Theodora Mistras as chief financial officer effective end of May 2026. Mistras joins from Viatris ( VTRS ), where she served as CFO since 2024. She succeeds Scott Ullem, who is transitioning after over a decade in the role. Mistras brings extensive experience in healthcare finance, including roles at Citigroup Global Markets and Goldman Sachs. More on Edwards Lifesciences Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript Edwards Lifesciences: More Appeal For The Heart Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript Edwards forecasts 9%-11% 2026 sales growth and $2.95-$3.05 adjusted EPS as TAVR guide rises to 7%-9% Edwards Lifesciences raises 2026 revenue guidance on bullish Q1 results